Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shu-Gan Jie-Yu capsule for diarrhea-predominant irritable bowel syndrome with depressive symptoms
ChiCTR1900021225Phase 4Recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jul 2018
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shugan Jieyu in Diarrhea-predominant irritable bowel syndrome (IBS-D) and major depressive disorder (MDD) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: IBS Symptom Severity Score. Started Jul 2018; status: recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1900021225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021225.